{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T04:09:07Z","timestamp":1793074147469,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.cllc.2020.06.019","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T11:59:02Z","timestamp":1593431942000},"page":"e470-e480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non\u2013small-cell Lung Cancer in US Community Practices"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6054-278X","authenticated-orcid":false,"given":"William","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron Scott","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2020.06.019_bib1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00428-016-2000-3","article-title":"Testing for ROS1 in non-small cell lung cancer: a review with recommendations","volume":"469","author":"Bubendorf","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.cllc.2020.06.019_bib3","series-title":"Xalkori [Prescribing Information]","year":"2019"},{"key":"10.1016\/j.cllc.2020.06.019_bib4","series-title":"Rozlytrek [Prescribing Information]","year":"2019"},{"key":"10.1016\/j.cllc.2020.06.019_bib5","series-title":"Zykadia [Prescribing Information]","year":"2019"},{"key":"10.1016\/j.cllc.2020.06.019_bib6","series-title":"Pfizer Inc. Lorbrena [Package Insert]","year":"2018"},{"key":"10.1016\/j.cllc.2020.06.019_bib8","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2020.06.019_bib9","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2014.58.3302","article-title":"Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort","volume":"33","author":"Mazi\u00e8res","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.06.019_bib10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ajh.25043","article-title":"Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): a phase 1b open-label study","volume":"93","author":"Gambacorti-Passerini","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cllc.2020.06.019_bib11","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.2017.75.5587","article-title":"Phase II study of crizotinib in East Asian patients with ROS1-positive advanced non-small-cell lung cancer","volume":"36","author":"Wu","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.06.019_bib12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.cllc.2020.06.019_bib13","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1200\/JCO.2016.71.3701","article-title":"Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement","volume":"35","author":"Lim","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.06.019_bib14","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.06.019_bib15","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.06.019_bib16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cllc.2018.10.006","article-title":"Results of a phase II placebo-controlled randomized discontinuation trial of cabozantinib in patients with non-small-cell lung carcinoma","volume":"20","author":"Hellerstedt","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2020.06.019_bib17","series-title":"Cabometyx [Prescribing Information]","year":"2019"},{"key":"10.1016\/j.cllc.2020.06.019_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.cllc.2020.06.019_bib19","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","volume":"36","author":"Kalemkerian","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.06.019_bib20","author":"Audibert"},{"key":"10.1016\/j.cllc.2020.06.019_bib22","series-title":"AJCC Cancer Staging Manual","year":"2011"},{"key":"10.1016\/j.cllc.2020.06.019_bib23","series-title":"AJCC Cancer Staging Manual","year":"2017"},{"key":"10.1016\/j.cllc.2020.06.019_bib25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1200\/EDBK_237863","article-title":"Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices","volume":"39","author":"Pennell","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.cllc.2020.06.019_bib26","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/03007995.2018.1533458","article-title":"Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients","volume":"35","author":"Davies","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cllc.2020.06.019_bib27","doi-asserted-by":"crossref","first-page":"e0156728","DOI":"10.1371\/journal.pone.0156728","article-title":"Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States","volume":"11","author":"Enewold","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2020.06.019_bib28","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cllc.2017.04.004","article-title":"Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities","volume":"18","author":"Gutierrez","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2020.06.019_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00159","article-title":"ALK testing trends and patterns among community practices in the United States","volume":"2","author":"Illei","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.cllc.2020.06.019_bib30","first-page":"e60","article-title":"Molecular testing patterns in metastatic non-small cell lung cancer","volume":"22","author":"MacLean","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.cllc.2020.06.019_bib31","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.cllc.2016.11.002","article-title":"Utilization patterns and trends in epidermal growth factor receptor (EGFR) mutation testing among patients with newly diagnosed metastatic lung cancer","volume":"18","author":"Shen","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2020.06.019_bib32","doi-asserted-by":"crossref","first-page":"e0206370","DOI":"10.1371\/journal.pone.0206370","article-title":"Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States","volume":"13","author":"Velcheti","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2020.06.019_bib33","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1001\/jama.2019.3241","article-title":"Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinicogenomic database","volume":"321","author":"Singal","year":"2019","journal-title":"JAMA"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420302138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420302138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:13:54Z","timestamp":1761506034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730420302138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1525730420302138"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2020.06.019","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Non\u2013small-cell Lung Cancer in US Community Practices","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2020.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}